283 related articles for article (PubMed ID: 30325794)
1. Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry.
Krüger K; Krauth C; Rossol S; Mauss S; Boeker KHW; Müller T; Klinker H; Pathil A; Heyne R; Stahmeyer JT;
Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):230-240. PubMed ID: 30325794
[TBL] [Abstract][Full Text] [Related]
2. Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial.
Stahmeyer JT; Krauth C; Bert F; Pfeiffer-Vornkahl H; Alshuth U; Hüppe D; Mauss S; Rossol S
J Viral Hepat; 2016 Feb; 23(2):105-15. PubMed ID: 26411532
[TBL] [Abstract][Full Text] [Related]
3. Real-world experience for the outcomes and costs of treating hepatitis C patients: Results from the German Hepatitis C-Registry (DHC-R).
Krüger K; Rossol S; Krauth C; Buggisch P; Mauss S; Stoehr A; Klinker H; Böker K; Teuber G; Stahmeyer J
Z Gastroenterol; 2023 May; 61(5):489-503. PubMed ID: 35839795
[TBL] [Abstract][Full Text] [Related]
4. Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy.
Langness JA; Tabano D; Wieland A; Tise S; Pratt L; Harrington LA; Lin S; Ghuschcyan V; Nair KV; Everson GT
Ann Hepatol; 2017; 16(3):366-374. PubMed ID: 28425406
[TBL] [Abstract][Full Text] [Related]
5. Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid.
Pham TT; Keast SL; Farmer KC; Thompson DM; Rathbun RC; Nesser NJ; Holderread BP; Skrepnek GH
J Manag Care Spec Pharm; 2018 Jul; 24(7):664-676. PubMed ID: 29952711
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility analysis of second-generation direct-acting antivirals for hepatitis C: a systematic review.
Puig-Junoy J; Pascual-Argente N; Puig-Codina L; Planellas L; Solozabal M
Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1251-1263. PubMed ID: 30791790
[TBL] [Abstract][Full Text] [Related]
7. Real-World Drug Costs of Treating Hepatitis C Genotypes 1-4 with Direct-Acting Antivirals: Initiating Treatment at Fibrosis 0-2 and 3-4.
Bach TA; Zaiken K
J Manag Care Spec Pharm; 2016 Dec; 22(12):1437-1445. PubMed ID: 27882839
[TBL] [Abstract][Full Text] [Related]
8. [Costs of a guideline-based treatment of patients with chronic hepatitis C in the era of interferon-free treatment].
Stahmeyer JT; Rossol S; Bert F; Liersch S; Krauth C
Z Gastroenterol; 2016 Aug; 54(8):760-9. PubMed ID: 27529526
[TBL] [Abstract][Full Text] [Related]
9. The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting.
Manos MM; Darbinian J; Rubin J; Ray GT; Shvachko V; Denis B; Velez F; Quesenberry C
J Manag Care Pharm; 2013; 19(6):438-47. PubMed ID: 23806057
[TBL] [Abstract][Full Text] [Related]
10. Direct costs of first-generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection.
Sethi N; Tapper EB; Vong A; Sethi S; Rourke M; Afdhal NH
J Viral Hepat; 2015 Dec; 22(12):974-6. PubMed ID: 26010946
[TBL] [Abstract][Full Text] [Related]
11. Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C.
Younossi ZM; Park H; Gordon SC; Ferguson JR; Ahmed A; Dieterich D; Saab S
Am J Manag Care; 2016 May; 22(6 Spec No.):SP205-11. PubMed ID: 27266950
[TBL] [Abstract][Full Text] [Related]
12. Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort.
Ruggeri M; Coretti S; Romano F; Kondili LA; Vella S; Cicchetti A
Value Health; 2018 Jul; 21(7):783-791. PubMed ID: 30005750
[TBL] [Abstract][Full Text] [Related]
13. Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients.
Su F; Beste LA; Green PK; Berry K; Ioannou GN
Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):686-693. PubMed ID: 28195877
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
15. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.
Backx M; Lewszuk A; White JR; Cole J; Sreedharan A; van Sanden S; Diels J; Lawson A; Neal KR; Wiselka MJ; Ito T; Irving WL
J Viral Hepat; 2014 Mar; 21(3):208-15. PubMed ID: 24438682
[TBL] [Abstract][Full Text] [Related]
16. Real-world experiences with direct-acting antiviral agents for chronic hepatitis C treatment.
Daniel KE; Saeian K; Rizvi S
J Viral Hepat; 2020 Feb; 27(2):195-204. PubMed ID: 31602715
[TBL] [Abstract][Full Text] [Related]
17. Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis.
Maan R; Zaim R; van der Meer AJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Manns MP; Zeuzem S; Hansen BE; Janssen H; Veldt BJ; de Knegt RJ; Uyl-de Groot CA
J Gastroenterol Hepatol; 2016 Nov; 31(11):1851-1859. PubMed ID: 26990109
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C.
Zhao YJ; Khoo AL; Lin L; Teng M; Koh CJ; Lim SG; Lim BP; Dan YY
J Gastroenterol Hepatol; 2016 Sep; 31(9):1628-37. PubMed ID: 26990023
[TBL] [Abstract][Full Text] [Related]
19. Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort.
Steinebrunner N; Stein K; Sandig C; Bruckner T; Stremmel W; Pathil A
World J Gastroenterol; 2018 Feb; 24(7):852-861. PubMed ID: 29467555
[TBL] [Abstract][Full Text] [Related]
20. Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study.
Stahmeyer JT; Rossol S; Bert F; Böker KH; Bruch HR; Eisenbach C; Link R; John C; Mauss S; Heyne R; Schott E; Pfeiffer-Vornkahl H; Hüppe D; Krauth C
PLoS One; 2016; 11(7):e0159976. PubMed ID: 27467772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]